48,833
edits
Line 4: | Line 4: | ||
*Evolving entity. | *Evolving entity. | ||
*Thought to be distinct from ''eosinophilic [[papillary renal cell carcinoma]]''.<ref name=pmid38456605>{{cite journal |authors=Castillo VF, Trpkov K, Van der Kwast T, Rotondo F, Hamdani M, Saleeb R |title=Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma |journal=Pathol Int |volume=74 |issue=4 |pages=222–226 |date=April 2024 |pmid=38456605 |doi=10.1111/pin.13417 |url=}}</ref><ref name=pmid37797754>{{cite journal |authors=Kim B, Lee S, Moon KC |title=Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors |journal=Hum Pathol |volume=142 |issue= |pages=1–6 |date=December 2023 |pmid=37797754 |doi=10.1016/j.humpath.2023.09.011 |url=}}</ref> | *Thought to be distinct from ''eosinophilic [[papillary renal cell carcinoma]]''.<ref name=pmid38456605>{{cite journal |authors=Castillo VF, Trpkov K, Van der Kwast T, Rotondo F, Hamdani M, Saleeb R |title=Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma |journal=Pathol Int |volume=74 |issue=4 |pages=222–226 |date=April 2024 |pmid=38456605 |doi=10.1111/pin.13417 |url=}}</ref><ref name=pmid37797754>{{cite journal |authors=Kim B, Lee S, Moon KC |title=Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors |journal=Hum Pathol |volume=142 |issue= |pages=1–6 |date=December 2023 |pmid=37797754 |doi=10.1016/j.humpath.2023.09.011 |url=}}</ref> | ||
*Early data suggests an indolent behaviour.<ref name=pmid31135486>{{cite journal |authors=Al-Obaidy KI, Eble JN, Cheng L, Williamson SR, Sakr WA, Gupta N, Idrees MT, Grignon DJ |title=Papillary Renal Neoplasm With Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study |journal=Am J Surg Pathol |volume=43 |issue=8 |pages=1099–1111 |date=August 2019 |pmid=31135486 |doi=10.1097/PAS.0000000000001288 |url=}}</ref> | |||
==Micro== | ==Micro== | ||
Line 41: | Line 42: | ||
It stains as follows: | It stains as follows: | ||
POSITIVE: CK7 (strong, diffuse), AE1/AE3 (strong, diffuse), GATA3 (moderate, diffuse), AMACR (moderate | POSITIVE: PAX8 (moderate, diffuse), CK7 (strong, diffuse), AE1/AE3 (strong, diffuse), GATA3 (moderate, diffuse), AMACR (moderate, diffuse). | ||
NEGATIVE: vimentin (stroma), CD117, CD10. | NEGATIVE: vimentin (stroma), CD117, CD10. | ||
Line 47: | Line 48: | ||
1. Pathol Int. 2024 Apr;74(4):222-226. doi: 10.1111/pin.13417. Epub 2024 Mar 8. | 1. Pathol Int. 2024 Apr;74(4):222-226. doi: 10.1111/pin.13417. Epub 2024 Mar 8. | ||
2. Hum Pathol. 2023 Dec:142:1-6. doi: 10.1016/j.humpath.2023.09.011. Epub 2023 Oct 4. | 2. Hum Pathol. 2023 Dec:142:1-6. doi: 10.1016/j.humpath.2023.09.011. Epub 2023 Oct 4. | ||
3. Am J Surg Pathol. 2019 Aug;43(8):1099-1111. doi: 10.1097/PAS.0000000000001288. | |||
3. Am J Surg Pathol. 2019 Aug;43(8):1099-1111. doi: 10.1097/PAS.0000000000001288. | |||
</pre> | </pre> | ||
Line 57: | Line 56: | ||
==References== | ==References== | ||
{{Reflist| | {{Reflist|2}} | ||
[[Category:Diagnosis]] | [[Category:Diagnosis]] | ||
[[Category:Kidney tumours]] |
edits